July 23, 2016 7:49 AM ET

Healthcare Equipment and Supplies

Company Overview of Ekso Bionics Holdings, Inc.

Company Overview

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Asia. The company operates through Engineering Services and Medical segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, stroke, and other lower limb paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The c...

1414 Harbour Way South

Suite 1201

Richmond, CA 94804

United States

Founded in 2005

95 Employees





Key Executives for Ekso Bionics Holdings, Inc.

Chief Executive Officer, President and Director
Age: 44
Total Annual Compensation: $225.0K
Co-Founder and President of Ekso Labs Division
Age: 39
Total Annual Compensation: $225.0K
Chief Financial Officer
Age: 54
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2015.

Ekso Bionics Holdings, Inc. Key Developments

Ekso Bionics Holdings, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 11:45 AM

Ekso Bionics Holdings, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 11:45 AM. Venue: Le Parker Meridien, New York, New York, United States.

Ekso Bionics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016

Ekso Bionics Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported total revenue was $8,486,000 compared to $1,689,000 during the same period of 2015. First quarter 2016 revenue includes $6.5 million of revenue resulting from one-time non-cash recognition of previously deferred medical device revenue for devices sold prior to 2016. Loss from operations was $6,642,000 against $4,093,000 a year ago. Net loss was $3,651,000, or $0.44 per basic and diluted share compared to $4,115,000 or $0.28 per basic and diluted share for the same period of 2015. Net loss applicable to common shareholders for the quarter included a non-cash preferred share deemed dividend of $3.1 million, offset by a non-cash gain of $3.0 million on the revaluation of a warrant liability.  Both non-cash items were associated with the company’s equity financing in December 2015.

Ekso Bionics Holdings, Inc., Q1 2016 Earnings Call, May 10, 2016

Ekso Bionics Holdings, Inc., Q1 2016 Earnings Call, May 10, 2016

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

December 4, 2015
Equipois, LLC

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ekso Bionics Holdings, Inc., please visit www.eksobionics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.